Your session is about to expire
← Back to Search
Bevacizumab for Ovarian Cancer
Study Summary
This trial is testing if Avastin can help to control ovarian, fallopian, or primary peritoneal cancer after it has been found during second-look surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has BRCA mutations or is HRD positive.I am planning to undergo ongoing cancer treatment after initial therapy.I have had blood clots in my arteries but am eligible if I've been treated for DVT.My blood counts and kidney, liver functions are within required ranges.I have recovered from my recent surgery and can start treatment within 7 weeks.My ovarian cancer is either mucinous or low-grade.I don't have chronic wounds or conditions that would make bevacizumab risky.I have previously been treated with bevacizumab or its equivalent.I've completed at least 6 cycles of specific chemotherapy for my cancer.I am not using, nor do I plan to use, any other cancer treatments besides the trial.I've had a follow-up surgery after successful initial cancer treatment and my tests show no signs of cancer.My ovarian cancer was confirmed during a follow-up surgery.I have advanced ovarian, fallopian tube, or peritoneal cancer.I am 18 years old or older.I have signed the consent form in my preferred language.My blood pressure is controlled with medication.I can take care of myself and am up and about more than half of my waking hours.I am using two birth control methods or am not having sex to join this study.I have had bleeding in my lungs, stomach, or brain.I agree to let my previously collected tissue samples be used for this study.You need to have a negative pregnancy test within 72 hours before starting the study medication, unless you cannot have children or have already gone through menopause.
- Group 1: Bevacizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being admitted to this clinical trial?
"Affirmative. Clinicaltrials.gov data confirms that this clinical trial is actively enrolling, with the first posting having been on November 1st 2016 and the most recent edit being made on January 3rd 2022. The study has need for 35 patients at a single medical centre."
Has Bevacizumab been granted authorization from the FDA?
"Evidence concerning the safety of Bevacizumab is limited to Phase 2 trials, so it received a score of two. No data exists that confirms its efficacy yet."
For what diseases and ailments is Bevacizumab commonly prescribed?
"Bevacizumab can be employed to combat malignant neoplasms, recurrent platinum-sensitive primary peritoneal cancer, and Stage IV epithelial ovarian cancer post-surgical excision."
Could you please provide a compendium of research regarding Bevacizumab?
"Presently, there are 355 clinical trials involving Bevacizumab with 89 of those studies being in Phase 3. Of the 17017 sites researching this medication, many reside in Taibei, Taiwan."
Are researchers currently recruiting participants for this investigation?
"The clinicaltrials.gov webpage indicates that this medical trial is currently accepting applicants, having opened on the 1st of November 2016 and been updated most recently on 3rd January 2022."
Share this study with friends
Copy Link
Messenger